转移性基底细胞癌的多中心真实世界分析:危险因素、治疗与结局
该研究回顾性分析了2005至2021年间4个学术中心收治的53例转移性基底细胞癌(mBCC)患者,比较淋巴结转移与远处转移两组在治疗结局和生存上的差异。结果显示,淋巴结转移患者完全缓解率更高,5年生存率也高于远处转移患者,但即使远处转移,5年生存率仍超过50%。
要点
- 淋巴结转移mBCC患者完全缓解率高于远处转移者。
- 淋巴结转移与远处转移的5年生存率分别为89.3%和61.0%。
- 远处转移患者更易持续带病或死于该病,但5年生存仍超50%。
核心结论
- 淋巴结转移的mBCC患者更易获得疾病缓解,而远处转移患者更易持续带病或死于该病。
- 即使为IV期远处转移,5年生存率仍超过50%。
主要发现
- 53例患者中,22例(42%)转移局限于淋巴结,31例(58%)有远处器官转移(伴或不伴淋巴结受累)。
- 淋巴结转移患者中半数(n=11)达到完全缓解,而远处转移患者中仅1例(3%)达到完全缓解。
- 淋巴结转移和远处转移患者的5年生存率分别为89.3%和61.0%。
局限性
- 因疾病罕见,样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastatic basal cell carcinoma (mBCC) is rare and there are limited data regarding patient and tumor risk factors, optimal treatments, and disease prognosis. OBJECTIVE: To assess patient and tumor characteristics, therapeutics, and outcomes of mBCC stratified by location of metastasis. METHODS: Retrospective cohort study of 53 patients with mBCC treated at 4 large academic centers in Boston, Massachusetts; Philadelphia, Pennsylvania; and Cleveland, Ohio between January 1, 2005 and December 31, 2021. RESULTS: A total of 53 patients with mBCC were identified across 4 centers, 22 (42%) of whom had mBCC with spread limited to lymph nodes and 31 (58%) patients with distant organ spread (with or without lymph node involvement). Overall, half (n = 11) of patients with nodal metastasis achieved complete remission of disease, compared with just 1 (3%) patient with distant metastasis. The 5-year survival for nodal and distant metastatic patients was 89.3% and 61.0%, respectively. LIMITATIONS: Small sample size due to disease rarity. CONCLUSIONS AND RELEVANCE: Patients with nodal disease are more likely to have disease remission whereas patients with distant metastasis are more likely to have persistent disease and die from their disease. However, 5-year survival rates exceed 50%, even for stage IV disease.
引用
- Groover M, Gupta N, Granger E, et al. A multicenter real-world analysis of risk factors, therapeutics, and outcomes of patients with metastatic basal cell carcinoma. J Am Acad Dermatol. 2023. PMID: 37949119. doi:10.1016/j.jaad.2023.10.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。